Voyager Therapeutics
VYGR
117 hedge funds and large institutions have $141M invested in Voyager Therapeutics in 2025 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 32 increasing their positions, 39 reducing their positions, and 18 closing their positions.
1,280% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $76K
37% more capital invested
Capital invested by funds: $103M → $141M (+$38M)
28% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 18
4% more funds holding
Funds holding: 112 → 117 (+5)
5.49% less ownership
Funds ownership: 59.95% → 54.47% (-5.5%)
18% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.03M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$736K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$723K |
| 4 |
Two Sigma Investments
New York
|
+$509K |
| 5 |
BC
Birchview Capital
Burlington,
Vermont
|
+$488K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$11.7M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.22M |
| 3 |
AC
Armistice Capital
New York
|
-$2.17M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$539K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$499K |
VYGR Hedge Fund Activity: Q3 2025 in Review
117 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q3 2025, worth a combined $141M — up 37% from $103M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new VYGR positions and 18 closed out — a net gain of 5 holders — while 32 added to existing stakes and 39 trimmed.
The largest buyer was Millennium Management, adding an estimated $5.03M. The largest seller was EcoR1 Capital, cutting an estimated $11.7M.
- 117 institutional investors held Voyager Therapeutics (VYGR) as of Q3 2025, up from 112 in Q2 2025.
- Funds reported $141M of Voyager Therapeutics stock for Q3 2025, up 37% quarter-over-quarter.
- 23 funds opened new Voyager Therapeutics positions in Q3 2025 and 18 closed out, a net change of +5 holders.
- The largest Voyager Therapeutics buyer in Q3 2025 was Millennium Management, an estimated $5.03M added.
- The largest Voyager Therapeutics seller in Q3 2025 was EcoR1 Capital, an estimated $11.7M sold.
Based on aggregated 13F filings for Q3 2025.